BUFFALO, NY -- (MARKET WIRE) -- 04/14/08 -- Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it will host a conference call at 10:00 a.m. EDT on April 17, to recap recent achievements and provide an update on the Company's development strategy and timeline.

Interested parties may participate by dialing 877-407-8031 (US) or 201-689-8031 (International) approximately five to ten minutes before the call start time. A live Webcast of the conference call will be available on the Cleveland BioLabs Web site at www.cbiolabs.com.

A replay of the call will be available starting on April 17, 2008, at 1:00 p.m. EDT through April 24, 2008 at 11:59 p.m. EDT. Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering account number 286 and conference ID number 281842. An archived Webcast of the conference call will be available on the Cleveland BioLabs Web site at www.cbiolabs.com.

On April 10, Cleveland BioLabs announced the publication of a breakthrough peer-reviewed paper on Protectan CBLB502's radioprotective capabilities in prestigious Science Magazine. The paper demonstrated the success of the Company's principle proprietary approach to protection of healthy tissue from a variety of deadly stresses and underscored Protectan CBLB502's potential as a radioprotector in both defense and medical settings.

On April 3, the Company publicized the award of a contract from the Department of Defense valued at up to $8.9 million for the advanced development of Protectan CBLB502 as a Medical Radiation Countermeasure to treat radiation injury following exposure to radiation from nuclear or radiological weapons.

On March 31, Cleveland BioLabs shared new study results demonstrating the efficacy of Protectan CBLB502 as a mitigator of hematopoietic damage from 75% lethal doses of radiation, up to 48 hours post exposure.

On February 19, the Company published results of a study demonstrating Protectan CBLB502's ability to reduce the side effects of a chemotherapeutic drug, cisplatinum (Ciplatin, Platinol) broadly used for treatment of ovarian, endometrial, head and neck, lung, stomach and other types of cancer.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the company's website at http://www.cbiolabs.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Some of the factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's periodic filings with the Securities and Exchange Commission.

Rachel Levine
Director Corporate Development & Communications
Cleveland BioLabs, Inc.
T: (646) 284-9439
E: rlevine@cbiolabs.com